<PAGE>   1
                                   FORM 10-K/A

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
    (Mark One)

            [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                   For the fiscal year ended December 31, 1997

                                       OR

          [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                         Commission file number: 0-12042


                                  BIOGEN, INC.
             (Exact name of Registrant as specified in its charter)


        Massachusetts                                         04-3002117
   (State or other jurisdiction                            (I.R.S. Employer
  of incorporation or organization)                        Identification No.)


                         14 Cambridge Center, Cambridge,
                    Massachusetts 02142 (Address of principal
                          executive offices)(zip code)

       Registrant's telephone number, including area code: (617) 679-2000


        Securities registered pursuant to Section 12(b) of the Act: None


 Securities registered pursuant to Section 12(g) of the Act: 
                                                    Common Stock, $.01 par value
                                                           (Title of class)


     Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                           Yes  X     No
                               ---       ---      

     Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]

     Aggregate market value of Common Stock held by nonaffiliates of the
Registrant at February 18, 1998: $3,132,883,164 (excludes shares held by
directors). Exclusion of shares held by any person should not be construed to
indicate that such person possesses the power, direct or indirect, to direct or
cause the direction of management or policies of the Registrant, or that such
person is controlled by or under common control with the Registrant. Common
Stock outstanding at February 18, 1998: 73,822,242 shares.

<PAGE>   2

PART IV
-------

ITEM 14.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K


     (3)  Exhibits


Exhibit No.       Description
-----------       -----------

(23)              Consent of Price Waterhouse LLP

(99.1)            Financial Statements for Biogen Savings Plan



<PAGE>   3

     Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.


BIOGEN, INC.

By: /s/ Michael J. Astrue
    ------------------------------
    Michael J. Astrue
    Vice President - General Counsel

Dated  June 30, 1998


<PAGE>   4


                                  EXHIBIT INDEX


Exhibit No.       Description
-----------       -----------

(23)              Consent of Price Waterhouse LLP

(99.1)            Financial Statements for Biogen Savings Plan